Bifidobacterium lactis inhibits NF-κB in intestinal epithelial cells and prevents acute colitis and colitis-associated colon cancer in mice

Authors

  • Seung Won Kim MS,

    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Hee Man Kim MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Kyoung Min Yang PhD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Sun-Ah Kim BS,

    1. Nutra R&BT, Seoul, Korea
    Search for more papers by this author
  • Sung-Kyu Kim BS,

    1. Nutra R&BT, Seoul, Korea
    Search for more papers by this author
  • Min Ji An MS,

    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Jae Jun Park MD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Sang Kil Lee MD, PhD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Tae Il Kim MD, PhD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Won Ho Kim MD, PhD,

    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    Search for more papers by this author
  • Jae Hee Cheon MD, PhD

    Corresponding author
    1. Department of Internal Medicine and Institute of Gastroenterology, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
    • Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-dong, Seodaemun-gu, Seoul 120-752, Korea
    Search for more papers by this author

  • Supported by a faculty research grant of Yonsei University College of Medicine for 2007 (6-20070224).

  • Presented during UEGW 2008 in Vienna, Austria.

Abstract

Background:

The aim of this study was to investigate the antiinflammatory effects of Bifidobacterium lactis on intestinal epithelial cells (IECs) and on experimental acute murine colitis and its tumor prevention effects on colitis-associated cancer (CAC) in mice.

Methods:

Human HT-29 cells were stimulated with IL-1β, lipopolysaccharides, or tumor necrosis factor-α with and without B. lactis, and the effects of B. lactis on nuclear factor kappa B (NF-κB) signaling in IEC were examined. For in vivo study, dextran sulfate sodium (DSS)-treated mice were fed with and without B. lactis. Finally, we induced colonic tumors in mice by azoxymethane (AOM) and DSS and evaluated the effects of B. lactis on tumor growth.

Results:

B. lactis significantly suppressed NF-κB activation, including NF-κB-binding activity and NF-κB-dependent reporter gene expression in a dose-dependent manner, and suppressed IκB-α degradation, which correlated with the downregulation of NF-κB-dependent gene products. Moreover, B. lactis suppressed the development of acute colitis in mice. Compared with the DSS group, the severity of DSS-induced colitis as assessed by disease activity index, colon length, and histological score was reduced in the B. lactis-treated group. In the CAC model, the mean number and size of tumors in the B. lactis-treated group were significantly lower than those in the AOM group.

Conclusions:

Our data demonstrate that B. lactis inhibits NF-κB and NF-κB-regulated genes in IEC and prevents acute colitis and CAC in mice. These results suggest that B. lactis could be a potential preventive agent for CAC as well as a therapeutic agent for inflammatory bowel disease. (Inflamm Bowel Dis 2010)

Ancillary